中危急性肺栓塞患者的氧疗:一项随机试验
这项先导性随机试验将无低氧血症、血流动力学稳定且超声心动图显示右心室扩大的肺栓塞患者随机分配至抗凝加补充氧气48小时组或单纯抗凝组,主要终点为随机化后48小时超声心动图右心室大小正常化。因COVID-19大流行提前终止,共纳入70例有主要终点数据的患者。48小时右心室大小正常化在氧气组为14/33(42.4%),室内空气组为8/37(21.6%)(P = .08)。氧气组右心室/左心室比值从基线1.28 ± 0.28降至48小时1.01 ± 0.16(P < .001);室内空气组从1.21 ± 0.18降至1.08 ± 0.19(P < .01)。90天内发生1例大出血和1例死亡,均在室内空气组。作者认为该先导试验显示部分次要疗效结局改善,为确证性临床结局试验提供了支持。
要点
- 无低氧血症的中危肺栓塞患者中,补充氧气48小时未显著提高右心室大小正常化比例(42.4% vs 21.6%,P = .08)。
- 氧气组右心室/左心室比值从基线1.28 ± 0.28降至48小时1.01 ± 0.16(P < .001),室内空气组从1.21 ± 0.18降至1.08 ± 0.19(P < .01)。
- 试验因COVID-19大流行提前终止,仅70例有主要终点数据,作者认为结果为小样本所限。
- 90天内1例大出血和1例死亡,均发生在室内空气组。
- 作者认为该先导试验显示部分次要疗效结局改善,为确证性临床结局试验提供了支持。
适用人群与场景
- 无低氧血症、血流动力学稳定且超声心动图显示右心室扩大的中危肺栓塞患者。
处置流程与药物剂量
- 抗凝加补充氧气48小时 vs 单纯抗凝。
研究设计与关键结果
- 先导性随机试验因COVID-19大流行提前终止,共70例有主要终点数据(平均年龄67.3 ± 16.1岁;女性36例[51.4%])。
- 随机化后48小时右心室大小正常化:氧气组14/33(42.4%)vs 室内空气组8/37(21.6%)(P = .08)。
- 氧气组右心室/左心室比值从基线1.28 ± 0.28降至48小时1.01 ± 0.16(P < .001);室内空气组从基线1.21 ± 0.18降至48小时1.08 ± 0.19(P < .01)。
- 90天内发生1例大出血和1例死亡,均在室内空气组。
证据类型、等级与局限
- 证据类型:先导性随机试验。
- 局限:作者指出分析受样本量小限制;试验因COVID-19大流行提前终止。
对床旁实践的改变
- 作者认为该先导试验显示部分次要疗效结局改善,为确证性临床结局试验提供了支持。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The effect of supplemental oxygen therapy in patients with intermediate-risk pulmonary embolism (PE) who do not have hypoxemia at baseline is uncertain.
RESEARCH QUESTION: Does supplemental oxygen improve echocardiographic parameters in nonhypoxemic patients with intermediate-risk PE?
STUDY DESIGN AND METHODS: This pilot trial randomly assigned nonhypoxemic patients with stable PE and echocardiographic right ventricle (RV) enlargement to receive anticoagulation plus supplemental oxygen for the first 48 h vs anticoagulation alone. The primary outcome was normal echocardiographic RV size 48 h after randomization. Secondary efficacy outcomes were the numerical change in the RV to left ventricle (LV) diameter ratio measured 48 h and 7 days after randomization with respect to the baseline ratio measured at inclusion.
RESULTS: The study was stopped prematurely because of the COVID-19 pandemic after recruiting 70 patients (mean ± SD age, 67.3 ± 16.1 years; 36 female [51.4%]) with primary outcome data. Forty-eight h after randomization, normalization of the RV size occurred in 14 of the 33 patients (42.4%) assigned to oxygen and in eight of the 37 patients (21.6%) assigned to ambient air (P = .08). In the oxygen group, the mean RV to LV ratio was reduced from 1.28 ± 0.28 at baseline to 1.01 ± 0.16 at 48 h (P < .001); in the ambient air group, mean RV to LV ratios were 1.21 ± 0.18 at baseline and 1.08 ± 0.19 at 48 h (P < .01). At 90 days, one major bleeding event and one death (both in the ambient air group) had occurred.
INTERPRETATION: In analyses limited by a small number of enrollees, compared with ambient air, supplemental oxygen did not significantly increase the proportion of patients with nonhypoxemic intermediate-risk PE whose RV to LV ratio normalized after 48 h of treatment. This pilot trial showed improvement in some ancillary efficacy outcomes and provides support for a definitive clinical outcomes trial.
TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT04003116; URL: www.
CLINICALTRIALS: gov.
参考来源
- Barrios D, Durán D, Rodríguez C, et al. Oxygen Therapy in Patients With Intermediate-Risk Acute Pulmonary Embolism: A Randomized Trial. Chest. 2023. PMID: 37717936. doi:10.1016/j.chest.2023.09.007
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。